The most common side effects of these medications are gastrointestinal (GI) issues like nausea, diarrhea, and abdominal pain
Lawsuits are being filed nationwide against Novo Nordisk, the drugs manufacturer, for failing to adequately warn consumers about serious side effects such as gastroparesis, stomach paralysis, prolonged nausea, and bowel obstruction
Only 4-7% of participants in SURMOUNT-1 and 2 discontinued the medication due to AE (Tables 2, 3)
Still deciding between semaglutide and tirzepatide
What It Targets Liraglutide is designed to target: Excess weight and obesity where diet and exercise alone have not led to sufficient, sustained loss. Weightrelated metabolic markers such as elevated blood sugar, prediabetes, insulin resistance, and dyslipidemia. Cravings, portion control challenges, and emotional eating patterns that benefit from strong biological satiety support. Clients motivated to pair medication with structured nutrition, movement, and behavior change for longterm results
For the fully insured market, BCBS Michigan will end coverage of GLP-1 medications completely beginning on renewal or January 2025, whichever is first